Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Cardiology
•
Advanced Heart Failure and Transplant
Are there other scenarios besides prior history of TIA or stroke or LV dysfunction in which systemic anticoagulation for LV non-compaction would be considered?
Related Questions
What is your approach to anticoagulation in patients with hypertrophic cardiomyopathy and an apical aneurysm?
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
What are reasonable alternatives to invasive angiography for CAV surveillance in patients who are a few years out from cardiac transplant with impaired renal function?
With the FDA recently approving acoramidis for ATTR cardiac amyloidosis, how should should we decide on optimal drug therapy and options for our patients?
Does the presence of diastolic dysfunction guide subsequent pharmacological, pacing and ablative therapies for atrial fibrillation?
How do you decide when to refer patients with obstructive hypertrophic cardiomyopathy for alcohol septal ablation versus septal myectomy?
What are some immunosuppression regimens to consider in a patient with refractory cardiac sarcoidosis?
When would be your threshold to consider obtaining an exercise RHC for undifferentiated dyspnea to help diagnose HFpEF?
Can mavacamten be considered for patients with HCM and ongoing dyspnea in setting of an elevated LVEDP but without significant LV outflow obstruction on imaging?
Is there a role of maximizing GDMT medications for patients with durable VADs?
